

country's growing infrastructure needs. The ACS is the only available survey that can provide these levels of data in a timely, consistent, and standardized manner.

To evaluate the proposed changes, the 2022 Content Test will include a control and two experimental treatments. The Control Treatment will include the current ACS (production) version of the questions. New topics will also be included in this treatment. The Test Treatment will include the test question version for all topics except household roster. Because changes to within-household coverage can impact results of person-level questions, the household roster question(s) will be the current production version in order to avoid confounding. Changes to the roster question(s) will be tested in a separate treatment, called the Roster Treatment. Additionally, health insurance coverage, labor force, and income will include a second set of experimental questions to be tested in the Roster Treatment.

Each topic will be evaluated using a variety of metrics, including item missing data rates, response distributions, comparisons to benchmarks and administrative data, response reliability, and other topic-specific metrics. Comparisons will be made between the Control Treatment and the experimental treatments. In some cases, the two experimental treatments will also be compared. Results of the test will inform decisions about changing content on the ACS.

Affected Public: Individuals or households.

Frequency: One-time test.

Respondent's Obligation: Mandatory.

Legal Authority: Title 13 U.S.C. Sections 141, 193, and 221.

This information collection request may be viewed at www.reginfo.gov. Follow the instructions to view the Department of Commerce collections currently under review by OMB.

Written comments and recommendations for the proposed information collection should be submitted within 30 days of the publication of this notice on the following website www.reginfo.gov/public/do/PRAMain. Find this particular information collection by selecting "Currently under 30-day Review—Open for Public Comments" or by using the search function and

entering either the title of the collection or the OMB Control Number 0607–0936.

Sheleen Dumas,

Department PRA Clearance Officer, Office of the Chief Information Officer, Commerce Department.

[FR Doc. 2022–05937 Filed 3–18–22; 8:45 am]

BILLING CODE 3510–07–P

DEPARTMENT OF COMMERCE

Foreign-Trade Zones Board

[B–8–2022]

Foreign-Trade Zone (FTZ) 43—Battle Creek, Michigan; Notification of Proposed Production Activity; Pfizer, Inc. (Lipid Active Pharmaceutical Ingredients), Kalamazoo, Michigan

Pfizer, Inc. (Pfizer) submitted a notification of proposed production activity to the FTZ Board (the Board) for its facility in Kalamazoo, Michigan within Subzone 43E. The notification conforming to the requirements of the Board's regulations (15 CFR 400.22) was received on March 11, 2022.

Pursuant to 15 CFR 400.14(b), FTZ production activity would be limited to the specific foreign-status materials/components and specific finished products described in the submitted notification (summarized below) and subsequently authorized by the Board. The benefits that may stem from conducting production activity under FTZ procedures are explained in the background section of the Board's website—accessible via www.trade.gov/ftz. The proposed finished products and materials/components would be added to the production authority that the Board previously approved for the operation, as reflected on the Board's website.

The proposed finished products include active pharmaceutical ingredients for Pfizer's COVID–19 vaccine—Lipid ALC-0159 K Finished and Lipid ALC-0315 Crude (duty rate is 3.7% or 6.5%).

The proposed foreign-status materials and components include: Methoxy Polyethylene Glycol (MPEG) Acid; Enzyme CDX-616; Registered Starter Chemical PF-07321332; 2,2,6,6-Tetramethylpiperidine-1-Oxyl; 1-Propanephosphonic Acid Cyclic Anhydride; 4-Amino-1-Butanol; Tetamine NS Succinate Salt; and, 2-Hexyldecanoic Acid (duty rate ranges from duty free to 6.5%). The request indicates that certain materials/components are subject to duties under Section 301 of the Trade Act of 1974 (Section 301), depending on the country

of origin. The applicable Section 301 decisions require subject merchandise to be admitted to FTZs in privileged foreign status (19 CFR 146.41).

Public comment is invited from interested parties. Submissions shall be addressed to the Board's Executive Secretary and sent to: ftz@trade.gov. The closing period for their receipt is May 2, 2022.

A copy of the notification will be available for public inspection in the "Online FTZ Information System" section of the Board's website.

For further information, contact Diane Finver at Diane.Finver@trade.gov.

Dated: March 15, 2022.

Andrew McGilvray,

Executive Secretary.

[FR Doc. 2022–05810 Filed 3–18–22; 8:45 am]

BILLING CODE 3510–DS–P

DEPARTMENT OF COMMERCE

Bureau of Industry and Security

Emerging Technology Technical Advisory Committee; Notice of Partially Closed Meeting

The Emerging Technology Technical Advisory Committee (ETTAC) will meet on April 8, 2022, at 11 a.m., Eastern Daylight Time. The meeting will be available via teleconference. The Committee advises the Office of the Assistant Secretary for Export Administration on the identification of emerging and foundational technologies with potential dual-use applications as early as possible in their developmental stages both within the United States and abroad.

Agenda

Open Session

1. Welcome and Introductions.
2. Introduction by the Bureau of Industry and Security Leadership.
3. *Presentation:* Bringing the Chipmakers Home—Attracting Manufacturers and the Talent to Sustain Them. Questions and Answers.
4. Public Comments/Announcements.

Closed Session

5. Discussion of matters determined to be exempt from the provisions relating to public meetings found in 5 U.S.C. App. 10(a)(1) and 10(a)(3).

The open session will be accessible via teleconference. To join the conference, submit inquiries to Ms. Yvette Springer at Yvette.Springer@bis.doc.gov no later than April 1, 2022.

To the extent time permits, members of the public may present oral statements to the Committee. The public